These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10. Islam T, Wolf G. Cancer Biomark; 2009; 5(2):69-73. PubMed ID: 19414923 [Abstract] [Full Text] [Related]
3. Atorvastatin and uptake of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) in human monocyte-macrophages: implications for magnetic resonance imaging. Müller K, Skepper JN, Tang TY, Graves MJ, Patterson AJ, Corot C, Lancelot E, Thompson PW, Brown AP, Gillard JH. Biomaterials; 2008 Jun; 29(17):2656-62. PubMed ID: 18377983 [Abstract] [Full Text] [Related]
4. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling. Yancy AD, Olzinski AR, Hu TC, Lenhard SC, Aravindhan K, Gruver SM, Jacobs PM, Willette RN, Jucker BM. J Magn Reson Imaging; 2005 Apr; 21(4):432-42. PubMed ID: 15779033 [Abstract] [Full Text] [Related]
5. Ultrasmall superparamagnetic iron-oxide-enhanced MR imaging of normal bone marrow in rodents: original research original research. Simon GH, Raatschen HJ, Wendland MF, von Vopelius-Feldt J, Fu Y, Chen MH, Daldrup-Link HE. Acad Radiol; 2005 Sep; 12(9):1190-7. PubMed ID: 16099684 [Abstract] [Full Text] [Related]
8. USPIO (Ferumoxtran-10)-enhanced MRI to visualize reticuloendothelial system cells in neonatal rats: feasibility and biodistribution study. Azoulay R, Olivier P, Baud O, Verney C, Santus R, Robert P, Gressens P, Sebag G. J Magn Reson Imaging; 2008 Oct; 28(4):1046-52. PubMed ID: 18821607 [Abstract] [Full Text] [Related]
9. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study. Okon E, Pouliquen D, Okon P, Kovaleva ZV, Stepanova TP, Lavit SG, Kudryavtsev BN, Jallet P. Lab Invest; 1994 Dec; 71(6):895-903. PubMed ID: 7807971 [Abstract] [Full Text] [Related]
10. Physical and biological characterization of superparamagnetic iron oxide- and ultrasmall superparamagnetic iron oxide-labeled cells: a comparison. Sun R, Dittrich J, Le-Huu M, Mueller MM, Bedke J, Kartenbeck J, Lehmann WD, Krueger R, Bock M, Huss R, Seliger C, Gröne HJ, Misselwitz B, Semmler W, Kiessling F. Invest Radiol; 2005 Aug; 40(8):504-13. PubMed ID: 16024988 [Abstract] [Full Text] [Related]
11. Magnetic resonance imaging of liver metastases: experimental comparison of anionic and conventional superparamagnetic iron oxide particles with a hepatobiliary contrast medium during dynamic and uptake phases. Kaufels N, Korn R, Wagner S, Schink T, Hamm B, Taupitz M, Schnorr J. Invest Radiol; 2008 Jul; 43(7):496-503. PubMed ID: 18580332 [Abstract] [Full Text] [Related]
13. Clearance of iron oxide particles in rat liver: effect of hydrated particle size and coating material on liver metabolism. Briley-Saebo KC, Johansson LO, Hustvedt SO, Haldorsen AG, Bjørnerud A, Fayad ZA, Ahlstrom HK. Invest Radiol; 2006 Jul; 41(7):560-71. PubMed ID: 16772849 [Abstract] [Full Text] [Related]
15. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Bourrinet P, Bengele HH, Bonnemain B, Dencausse A, Idee JM, Jacobs PM, Lewis JM. Invest Radiol; 2006 Mar; 41(3):313-24. PubMed ID: 16481915 [Abstract] [Full Text] [Related]